Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
GAITHERSBURG, Md., July 20, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) will release its second quarter financial results immediately after market close on Thursday, August 3, 2017. The company will then conduct a conference call at 5:00 pm (Eastern Time) on the same day to discuss the financial results for the second quarter and year to date periods of 2017, recent business developments, revenue guidance for the third quarter of 2017, and revenue and net income guidance for full year 2017.
This conference call can be accessed live by telephone or via webcast:
Live Teleconference Information:
Dial in number: (855) 766-6521
Conference ID: 29703370
Live Webcast Information:
Visit edge.media-server.com/m/p/g8vcpsxx for the live webcast feed.
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Lynn Kieffer Vice President, Corporate Communications 240-631-3391 [email protected]
